BRUFEN RAPID Price

Overview

Welcome to Dwaey, specifically on BRUFEN RAPID Capsules (Soft Gelatin) page.
This medicine contains an important and useful components, as it consists of Ibuprofen.
BRUFEN RAPID is available in the market in concentration 400mg/Capsule and in the form of Capsules (Soft Gelatin).

ABBOTT LABORATORIES S.A. is the producer of BRUFEN RAPID and it is imported from UAE, The most popular alternatives of BRUFEN RAPID are listed downward .

Mode Of Action

Ibuprofen inhibits synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase-1 and 2. It has anti-inflammatory, analgesic and antipyretic properties.

Indication

• Rheumatoid arthritis
• Osteoarthritis
• Pain
• Fever
• Pericarditis
• Dysmenorrhea
• Patent ductus arteriosus
• Inflammation
• Musculoskeletal and joint disorders

Precaution

Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation. Lactation: Drug excreted into breast milk; use not recommended (American Academy of Pediatrics committee states that drug is compatible with nursing)

Side Effects

• 1-10% Dizziness (3-9%)
• Epigastric pain (3-9%)
• Heartburn (3-9%)
• Constipation (1-3%)
• Nausea (3-9%)
• Rash (3-9%)
• Tinnitus (3-9%)
• Edema (1-3%)
• Fluid retention (1-3%)
• Headache (1-3%)
• Vomiting (1-3%) <1% Acute renal failure (sometimes with acute tubular necrosis or hyperkalemia
• polyuria
• azotemia
• cystitis
• hematuria
• decreased creatinine clearance
• elevations in blood urea nitrogen (BUN) or creatinine without other manifestations of renal failure) Agranulocytosis
• Aplastic anemia
• Erythema multiforme
• Erythematous macular rashes
• Exfoliative dermatitis
• Hemolytic anemia (with or without positive direct antiglobulin test results)
• Neutropenia
• Thrombocytopenia (with or without purpura)
• Toxic epidermal necrolysis (Lyell syndrome) and photosensitivity reactions Potentially Fatal: Severe CV thrombotic events. Severe GI bleeding
• ulceration and perforation.

Contra indication

Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: C; D in 3rd trimester or near delivery. At >30 weeks' gestation; may cause premature closure of ductus arteriosus